Search research articles
Contact Us
Filters
Showing results (171-180 of 180) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 180 results.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study
P Andena, G Tine, F Nichetti, et al.
ESMO Open
|
January 5, 2021
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center
G Quero, L Salvatore, C Fiorillo, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
ESMO Open
|
August 15, 2021
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
G Orsi, M Di Marco, A Cavaliere, et al.
ESMO Open
|
January 5, 2021
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
U Peretti, A Cavaliere, M Niger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
D Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open
|
June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
D Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
ESMO Open
|
March 19, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open
|
October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy
L Boscolo Bielo, S Napolitano, A Avallone, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 180) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 180 results.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study
P Andena, G Tine, F Nichetti, et al.
ESMO Open
|
January 5, 2021
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center
G Quero, L Salvatore, C Fiorillo, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
ESMO Open
|
August 15, 2021
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
G Orsi, M Di Marco, A Cavaliere, et al.
ESMO Open
|
January 5, 2021
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
U Peretti, A Cavaliere, M Niger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
D Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open
|
June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
D Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
ESMO Open
|
March 19, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open
|
October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy
L Boscolo Bielo, S Napolitano, A Avallone, et al.
Page
of 18